Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.
Rondo Therapeutics has raised $67.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
Rondo Therapeutics's investors include SV Health Investors, Canaan Partners, Novo Holdings, Johnson & Johnson Innovation, Red Tree Venture Capital.
Rondo Therapeutics is headquartered in Hayward, United States.
Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.
Rondo Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rondo Therapeutics — Funding & Investors." VCBacked, March 2, 2022, https://www.vcbacked.co/company/rondo-therapeutics. Accessed August 8, 2026.
VCBacked. (2022). Rondo Therapeutics — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/rondo-therapeutics
{{cite web |title=Rondo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rondo-therapeutics |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated